Thank you for joining us in 2022!

Clinical Trials and Cancer Immunotherapy: Accessing Promising Treatments

November 11, 2022, 1:45 pm -
2:15 pm
Myth-busting patient participation in medical studies

Session Description

Clinical trials are essential to bringing promising new therapies to patients, often for the first time or in new combinations with other treatments. What is a clinical trial? What are common misconceptions about clinical trials? How can you access and enroll in a cancer immunotherapy clinical trial? How has the COVID-19 pandemic changed patient participation in cancer clinical trials? These are just few of the questions that Dr. Peter Fecci, Professor of Neurosurgery, Pathology, Immunology, and Biomedical Engineering at Duke University, will address during this informative and myth-busting session. Following his talk, you’ll have an opportunity to ask your questions about clinical trials during a live Q&A session.


Peter E. Fecci, MD, PhD

Duke Cancer Center, DukeHealth, and Duke University

Peter Fecci, MD PhD, is currently a Professor of Neurosurgery, Pathology, Immunology, and Biomedical Engineering at Duke University, where he also serves as the Director for the Duke Center for Brain and Spine Metastasis, as well as for the Duke Brain Tumor Immunotherapy Program. A neurosurgeon-scientist, Dr. Fecci focuses clinically on intrinsic brain tumors, both primary and metastatic. In the research realm, he heads an NIH-funded laboratory that focuses on integrating strategies for reversing cancer-induced T cell dysfunction with current immune-based platforms. For his research contributions, he was a recent recipient of the Cancer Research Institute Lloyd J. Old STAR Award and was likewise inducted into the American Society for Clinical Investigation. Dr. Fecci also serves as multi-PI for the Duke R25 training grant. His recent work on brain tumor-induced T cell sequestration and exhaustion has produced numerous high-profile publications. He is now actively engaged in exploring novel drug targets and therapeutics that his group has uncovered for side-stepping brain tumor-imposed immune dysfunction and for newly licensing immune-based approaches in this patient population.